BMI Most Impairs Treatment Response in Rheumatoid Arthritis Save
Using a large cohort of rheumatoid arthritis (RA) patients, Tumor-Necrosis Factor inhibitors (TNFi) were compared to non-TNFi biologic therapies and showed that poorer responses were seen in obese and underweight patients, with no clear superiority of non-TNFi therapy over TNFi therapy in any BMI category.
RA cohort data from the CorEvitas (CORRONA) registry were analyzed for clinical outcomes with patient weight (BMI) further subcategorizing patients.
The study included 2891 TNFi and 3010 non-TNFi initiators.
Obese patients had a significantly lower odds of achieving LDA or MCID and less improvement in CDAI,
Low BMI was also associated with reduced response rates with lower odds of LDA [OR (95% CI): 0.32 (0.15,0.71) p=0.005].
Across BMI categories , there was no difference in outcomes between TNFi and non-TNFi therapies treated patients..
Weight, rather than a particular biologic, most influence clinical responses.
Continue Reading
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.